ChronoScale to divest Ekso and focus on cloud

ChronoScale Corporation announced that its Board approved a plan on May 29, 2026 to divest its wholly owned subsidiary, Ekso Bionics, Inc., and concentrate operations solely on its cloud business.

Rhea-AI Filing Summary

ChronoScale Corporation announced that its Board approved a plan on May 29, 2026 to divest its wholly owned subsidiary, Ekso Bionics, Inc., and concentrate operations solely on its cloud business.

The company expects to complete the Ekso divestiture during the first fiscal quarter. It anticipates material charges related to severance costs, lease termination payments, transaction expenses, and other exit costs. ChronoScale has not yet determined reliable estimates for these charges and plans to amend the report within four business days after setting those estimates, as required.

Insights

Equity analyst

ChronoScale is exiting Ekso Bionics to become a pure cloud-focused business, with unspecified but material exit costs.

ChronoScale Corporation plans to divest its wholly owned subsidiary Ekso Bionics, Inc. and redirect attention to its cloud operations. This represents a strategic shift away from the Ekso business toward a more focused company profile centered on cloud services.

The company expects “material” charges, including severance, lease termination payments, transaction expenses, and other exit costs, but has not yet determined reliable estimates. Financial impact will depend on the eventual sale or wind-down terms and the level of these charges once quantified.

The divestiture is expected to be completed during the first fiscal quarter, with ChronoScale committing to amend its report within four business days after determining cost estimates. Future company filings will clarify the scale of these charges and how the cloud-only strategy shapes ongoing operations.

8-K Event Classification

Item 2.05 — Costs Associated with Exit or Disposal Activities

1 item

Item 2.05 Costs Associated with Exit or Disposal Activities Financial

The company committed to an exit plan involving layoffs, facility closures, or restructuring charges.

Key Terms

Item 2.05 Costs Associated with Exit or Disposal Activities, divest, severance costs, lease termination payments, +2 more

6 terms

Item 2.05 Costs Associated with Exit or Disposal Activities regulatory

"Item 2.05 Costs Associated with Exit or Disposal Activities."

divest financial

"committed to a plan to divest its wholly owned subsidiary, Ekso Bionics, Inc."

severance costs financial

"material charges, including severance costs, lease termination payments, transaction-related expenses"

lease termination payments financial

"including severance costs, lease termination payments, transaction-related expenses"

forward-looking statements regulatory

"contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995"

Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.

Private Securities Litigation Reform Act of 1995 regulatory

"forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did ChronoScale Corporation (CHRN) announce regarding Ekso Bionics?

ChronoScale’s Board approved a plan to divest its wholly owned subsidiary Ekso Bionics, Inc. The company intends to focus its operations solely on its cloud business after this exit, signaling a strategic shift away from the Ekso segment.

When does ChronoScale (CHRN) expect to complete the Ekso Bionics divestiture?

ChronoScale expects to complete the divestiture of the Ekso business during the first fiscal quarter. The exact closing timing is not specified, but this timeframe indicates management’s intention to move relatively quickly with the planned exit.

What types of costs will ChronoScale (CHRN) incur from exiting Ekso Bionics?

ChronoScale expects material charges related to severance costs, lease termination payments, transaction-related expenses, and other exit costs. These charges arise from reducing staff, ending facilities arrangements, and executing either a sale or wind-down of the Ekso Bionics business.

Has ChronoScale (CHRN) estimated the total exit charges for the Ekso Bionics divestiture?

ChronoScale stated it is not yet able to make a good-faith estimate of total exit charges or amounts by category. It will amend its report within four business days after determining those estimates, in line with Item 2.05(d) requirements.

What risks did ChronoScale (CHRN) highlight about the Ekso Bionics divestiture?

ChronoScale noted that actual results may differ due to changes in estimated exit costs, the timing and completion of the divestiture, its ability to execute a wind-down or sale of Ekso, and broader economic, market, and business conditions.

How will ChronoScale (CHRN) communicate updates on the Ekso Bionics exit costs?

ChronoScale undertook to amend its report within four business days after it determines estimates or ranges for the expected charges. This amendment will provide investors with more detailed information on the financial impact of the Ekso divestiture.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/04/2026 - 04:15 PM Learn about SEC filing dates

false 0001549084 0001549084 2026-05-29 2026-05-29 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): May 29, 2026

CHRONOSCALE CORPORATION

(Exact name of registrant as specified in its charter)

Nevada		001-37854		99-0367049
(State or other jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification Number)

3811 Turtle Creek Blvd. Suite 2100 Dallas, Texas		75219
(Address of registrant’s principal executive office)		(Zip code)

 214-427-1704

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.001 per share		CHRN		Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.05 Costs Associated with Exit or Disposal Activities.

On May 29, 2026, the Board of Directors (the “Board”) of ChronoScale Corporation, a Nevada corporation (the “Company”) committed to a plan to divest its wholly owned subsidiary, Ekso Bionics, Inc., a Delaware corporation (“Ekso”) which had not previously been announced as being held for sale, and to focus the Company’s operations solely on its cloud business. The Company expects to complete the divesture of the Ekso business during the first fiscal quarter. In connection with this action, the Company expects to incur material charges, including severance costs, lease termination payments, transaction-related expenses, and other exit costs.

The Company is not yet able to make a good-faith estimate of the total amount or range of amounts expected to be incurred in connection with this action, or the amounts or range of amounts for each major type of charge. The Company undertakes to amend this Current Report on Form 8-K to include this information within four business days after it makes a determination of such estimates or range of estimates, as required by Item 2.05(d) of Form 8-K.

Forward-Looking Statements

This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the expected costs, timing, and financial impact of the planned divestiture of the Ekso business. Words such as “anticipates,” “expects,” “intends,” “plans,” “projects,” “believes,” “seeks,” “estimates,” “can,” “may,” “will,” “would” and similar expressions identify such forward-looking statements. These statements are not guarantees of results and should not be considered an indication of future activity or future performance. Actual results may differ materially from those expressed or implied by such forward-looking statements due to a variety of factors, including, but not limited to, changes in estimates of costs associated with the divestiture, including severance, lease termination expenses, and other exit-related charges; the timing and completion of the divestiture; the Company’s ability to successfully execute the wind-down or sale of the Ekso business; and general economic, market, and business conditions. The Company undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this report, except as required by law.

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: June 4, 2026

	CHRONOSCALE CORPORATION
	By:	/s/ Jerome Wong
	Name:	Jerome Wong
	Title:	Chief Financial Officer

3

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL SCHEMA FILE 3.0 KB
• EX-101 XBRL LABEL FILE 33.4 KB
• EX-101 XBRL PRESENTATION FILE 21.9 KB